Last month, the U.S. Food and Drug Administration (the “FDA”) announced in a Declaratory Order the resolution of the shortage of semaglutide ...

New Delhi: Citing that there is no real world long-term safety data for Novo Nordisk's antidiabetic drug Semaglutide tablets ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

Eli Lilly launches diabetes and obesity drug Mounjaro in India, offering innovative treatment for metabolic health management ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of ...

New weight loss drugs like Ozempic and Wegovy help suppress appetite, leading to significant weight loss, but they come with ...

It is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent ...

Mumbai-based Kilitch Drugs Ltd plans to enter biosimilars and oral solids, including diabetic and weight-loss tablets, and is ...

The company plans to enter biosimilars and oral solids, including diabetic and weight-loss tablets, and is expanding ... driven by the adoption of semaglutide (Wegovy) and tirzepatide (Mounjaro).